Stevanato Group S.p.A.
STVNHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Stevanato Group S.p.A. (STVN) is listed under Medical Instruments & Supplies. Valued at $5.32B, STVN is a mid-cap name in its sector. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
Market Cap
$5.32B
Beta
0.78
P/E (TTM)
34.19
P/E (Fwd)
23.61
EPS (TTM)
$0.57
EPS (Fwd)
$0.83
ROE
9.1%
ROA
5.5%
Cash
$79.1M
Total Debt
$445.3M
Free CF
-$104.7M
52W Change
-25.4%
Annual Financials
Cash vs Debt
Where STVN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, STVN finished 2.70% above its 150-day moving average ($18.52) and 4.85% above its 200-day moving average ($18.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is STVN overbought or oversold?
At the October 20, 2026 close, STVN's RSI(14) was 17.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Stevanato Group S.p.A. carries $445.3M in total debt against $79.1M in cash reserves — debt is roughly 5.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$104.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 9.1% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $983.7M (2022) to $1.19B (2025), reflecting a 21% increase over the period.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Stevanato Group S.p.A.'s trajectory.